Contineum Therapeutics (CTNM) vs Cypherpunk Technologies (CYPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 365.6% versus a loss of 39.5%. Cypherpunk Technologies is the larger company by market cap ($277.0 million vs $266.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | CYPH |
|---|---|---|
| Share price | $7.08 | $2.57 |
| Market cap | $266.36M | $276.95M |
| 1-day change | -10.38% | -14.90% |
| YTD return | -38.06% | +121.55% |
| 1-year return | -39.49% | +365.58% |
| 5-year return | — | -91.17% |
| P/E ratio (TTM) | — | 4.08 |
| EPS (TTM) | $-1.73 | $0.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-59.98M | $4.82M |
| 52-week high | $17.79 | $4.19 |
| 52-week low | $6.95 | $0.393 |
| Distance from 52-week high | -60.19% | -38.66% |
| Analyst consensus | buy | none |
| Avg. price target upside | +212.71% | +90.66% |
| Average volume | 732.62K | 10.92M |
| Shares outstanding | 32.96M | 107.76M |
| Employees | 51 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed CTNM by 405.1 percentage points over the past year.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
CTNM vs CYPH FAQ
Which is bigger, Contineum Therapeutics or Cypherpunk Technologies?
Cypherpunk Technologies (CYPH) is larger, with a market capitalization of $276.95M compared with $266.36M for Contineum Therapeutics (CTNM).
Which stock has performed better over the past year, CTNM or CYPH?
CYPH returned +365.58% over the past 12 months, compared with -39.49% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Cypherpunk Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.